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Objective. While phosphoinositide 3-kinases
(PI3Ks) are involved in various intracellular signal
transduction processes, the specific functions of the
different PI3K isoforms are poorly understood. We have
previously shown that the PI3K isoform is required for
arthritis development in the K/BxN serum–transfer
model. Since osteoclasts play a critical role in patho-
logic bone loss during inflammatory arthritis and other
diseases, we undertook this study to test the role of
PI3K in osteoclast development and function using a
combined genetic and pharmacologic approach.
Methods. The role of PI3K in primary human
and murine osteoclast cultures was tested with the
PI3K-selective inhibitor TGX221 and by using
PI3K/ mice. The trabecular bone architecture of
PI3K/ mice was evaluated using micro–computed
tomography and histomorphometric analyses.
Results. The expression of PI3K was strongly
and specifically up-regulated during in vitro osteoclast
differentiation. In vitro development of large multi-
nucleated osteoclasts from human or murine progeni-
tors and their resorption capacity were strongly reduced
by the PI3K inhibitor TGX221 or by the genetic
deficiency of PI3K. This was likely due to defective
cytoskeletal reorganization and vesicular trafficking,
since PI3K/ mouse multinucleated cells failed to
form actin rings and retained intracellular acidic vesi-
cles and cathepsin K. In contrast, osteoclast-specific
gene expression and the survival and apoptosis of
osteoclasts were not affected. PI3K/ mice had sig-
nificantly increased trabecular bone volume and showed
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abnormal osteoclast morphology with defective resorp-
tion pit formation.
Conclusion. PI3K plays an important role in
osteoclast development and function and is required for
in vivo bone homeostasis.
Phosphoinositide 3-kinases (PI3Ks) comprise a
diverse family of lipid kinases involved in nearly all
cellular functions as well as various disease processes
ranging from cancer to metabolic and inflammatory
diseases (1–6). The best known mammalian PI3Ks are
the class I PI3K family members PI3K, PI3K, PI3K,
and PI3K (2,7). PI3K, PI3K, and PI3K mainly relay
signals downstream from receptor or nonreceptor ty-
rosine kinases, whereas PI3K is primarily involved in
signal transduction by the  subunits of certain G
protein–coupled receptors (2,7).
The functional role of PI3Ks had initially been
addressed by using general PI3K inhibitors such as
wortmannin or LY294002. However, more recent stud-
ies using genetic deletion approaches and the recent
development of isoform-specific PI3K inhibitors have
revealed highly specific functions of the different iso-
forms in certain biologic processes, promising novel
therapeutic strategies for various disease states (2,4).
We previously demonstrated that PI3K is re-
quired for arthritis development in the K/BxN serum–
transfer model (8). Since that model mimics the myeloid
cell–mediated effector phase of arthritis, PI3K was
most likely required in one (or more) myeloid lineage
cell types.
Osteoclasts are highly specialized bone-resorbing
cells of myeloid hematopoietic cell origin (9–11) and are
responsible for basal bone resorption as well as patho-
logic bone loss during inflammatory arthritis, bone
metastasis, and postmenopausal osteoporosis. Their role
in inflammatory arthritis is indicated by reduced
arthritis-induced local bone resorption upon genetic or
pharmacologic blockade of osteoclasts, both in experi-
mental mice (12–14) and in patients with rheumatoid
arthritis (15).
Osteoclast development and function are di-
rected by a number of extracellular cues including
macrophage colony-stimulating factor (M-CSF),
RANKL, 3 integrin–mediated adhesive interactions,
and immunoreceptor-like activation signals (9–11,
16,17). Wortmannin and LY294002 inhibit both the
development and the resorptive activity of osteoclasts
(18–21). However, the role of the different PI3K iso-
forms in osteoclast development and function is poorly
understood.
These issues prompted us to analyze the role of
PI3K in primary in vitro osteoclast cultures and in
in vivo bone homeostasis, using a combined genetic and
pharmacologic approach. Our results indicate that
PI3K plays a major role in osteoclast development,
osteoclast-mediated bone resorption, and in vivo bone
homeostasis, likely due to its participation in the orga-
nization of the osteoclast cytoskeleton and the release of
intracellular vesicles.
MATERIALS AND METHODS
Animals. Pik3cbtm1.1Bvan/tm1.1Bvan (PI3K/) mice
carrying a homozygous deletion of exons 21–22 of Pik3b, the
gene encoding the p110 catalytic subunit of PI3K, were
described previously (22) and were maintained in hetero-
zygous form on a mixed C57BL/6:129Sv genetic background
(backcrossed to C57BL/6 for 4 generations). Age- and
sex-matched wild-type controls (mostly littermates) were ob-
tained from the same colony. Transgenic mice ubiquitously
expressing enhanced green fluorescent protein (EGFP)–
tagged Lifeact (23) were provided by Dr. Michael Sixt (Insti-
tute of Science and Technology, Klosterneuburg, Austria) and
were crossed with PI3K/ mice to obtain Lifeact–EGFP–
expressing PI3K/ mice. For pharmacologic studies,
C57BL/6 mice were purchased from Charles River.
Due to the limited availability of PI3K/ mice, bone
marrow cells for most in vitro osteoclast and macrophage
cultures were obtained from bone marrow chimeras generated
by transplanting PI3K/ (and parallel wild-type control)
mouse bone marrow cells to lethally irradiated recipients, as
previously described (24,25). No differences have been ob-
served between osteoclast cultures derived from intact mice
and those derived from corresponding bone marrow chimeras
of either genotype (data not shown).
Mice were kept in individually sterile ventilated cages
(Tecniplast) in a conventional facility. All animal experiments
were approved by the Semmelweis University Animal Experi-
mentation Review Board.
In vitro culture and resorption assays. In vitro oste-
oclast cultures were performed essentially as previously de-
scribed (26). Wild-type or PI3K/ mouse bone marrow cells
were first cultured in the presence of 10 ng/ml mouse M-CSF
(PeproTech) for 2 days. Nonadherent cells (referred to as
myeloid progenitors) were then plated at 2 105 cells/cm2 and
cultured in the presence of 20 or 50 ng/ml recombinant mouse
M-CSF and 20 or 50 ng/ml mouse RANKL (both from
PeproTech) with media/cytokine changes every 2 days. Osteo-
clast morphology was tested 3 days later, using a commercial
tartrate-resistant acid phosphatase (TRAP) staining kit
(Sigma) and imaged using a Leica DMI6000B inverted micro-
scope, and the number of osteoclasts (defined as TRAP-
positive cells with 3 nuclei) was counted manually. The
diameter of the cells was determined using ImageJ software
(National Institutes of Health). For in vitro resorption assays,
osteoclasts were cultured under similar conditions for 11 days
on an artificial hydroxyapatite layer (BD BioCoat Osteologic
slides) or on bovine cortical bone slices (Immunodiagnostic
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Systems), then processed according to the manufacturer’s
instructions, followed by imaging and determination of the
resorbed area using ImageJ software.
For osteoblast–osteoclast coculture experiments, cal-
variae of euthanized neonatal wild-type mice were digested by
0.1% collagenase and 0.25% trypsin–EDTA (both from
Sigma) in 5 consecutive rounds. The cells isolated during the
last 3 rounds were plated at 105 cells/well in 96-well plates and
cultured for 2 days in the presence of 10 nM 1,25-
dihydroxyvitamin D3 and 10 nM dexamethasone (both from
Sigma). Wild-type or PI3K/mouse bone marrow cells were
then seeded onto the osteoblasts at 5  104 cells/well and
cultured for 10 days with media changes every 2 days. TRAP
expression was then determined as described above. Wild-type
and PI3K/ mouse macrophages were generated by cultur-
ing myeloid progenitors in the presence of 50 ng/ml M-CSF
without the addition of RANKL.
Human osteoclasts were differentiated from peripheral
blood mononuclear cells (PBMCs) from healthy volunteers.
PBMCs were obtained by dextran sedimentation and centrif-
ugation through Ficoll-Paque (GE Healthcare) as previously
described (27). Mononuclear cells were washed and plated at
2  105 cells/cm2 to 24-well tissue culture plates or BD
BioCoat Osteologic slides and cultured in the presence of 20 or
50 ng/ml recombinant human M-CSF and 20 or 50 ng/ml
human RANKL (both from PeproTech) for 14 days with
media/cytokine changes every 2 days. TRAP staining and
resorption assays were performed as described above. Exper-
iments on human cells were approved by the Semmelweis
University Regional and Institutional Committee of Science
and Research Ethics.
For inhibitor studies, wortmannin (Sigma) and
TGX221 (Cayman Chemical) were added either concomitantly
with the intial RANKL treatment or 3 days later and then
replaced, with media changes every 2 days. Vehicle control
samples were treated with 0.1% DMSO or ethanol.
Detection of apoptosis. For survival analysis, pre-
osteoclasts obtained by culturing mouse myeloid progenitors
for 2 days in the presence of 50 ng/ml M-CSF and 50 ng/ml
RANKL were suspended by 0.25% trypsin–EDTA (Sigma)
and either analyzed immediately or cultured for an addi-
tional 12 or 18 hours in -minimum essential medium in
the absence of serum/cytokines. Cells were stained with
phycoerythrin-conjugated annexin V and 7-aminoactinomycin
D (7-AAD) (Apoptosis Detection Kit; BD PharMingen) ac-
cording to the manufacturer’s instructions and analyzed on a
BD FACSCalibur flow cytometer.
For the TUNEL reaction, osteoclast cultures were
stained with a Roche In Situ Cell Death Detection Kit, AP,
according to the manufacturer’s instructions. The number of
TUNEL-positive cells was counted manually.
Fluorescence microscopy. For F-actin staining, mouse
myeloid progenitors were cultured for the indicated time
periods in the presence of 50 ng/ml M-CSF and 50 ng/ml
RANKL with or without the indicated inhibitors, fixed with 4%
paraformaldehyde, permeabilized with 0.1% Triton X-100
(Sigma), and stained with 1:400 Alexa Fluor 488–conjugated
phalloidin (Invitrogen) and 1:1,000 DAPI (Invitrogen). After
several washes, fluorescence was observed using a Leica
DMI6000B inverted microscope.
For live imaging of osteoclast development, myeloid
progenitors obtained from Lifeact–EGFP–transgenic wild-
type or PI3K/ mice were cultured for the indicated time
period in the presence of 50 ng/ml M-CSF and 50 ng/ml
RANKL with or without the indicated inhibitors, and imaged
using an Essen BioScience IncuCyte Zoom imaging system
inside a tissue culture incubator or a Nikon BioStation IM-Q
imaging system (Auro-Science Hungary). Videos were gener-
ated using IncuCyte Zoom Controller 2013A or Nikon BioSta-
tion IM software. For acidic vesicle staining, mouse myeloid
progenitors cultured for 3 days in the presence of 50 ng/ml
M-CSF and 50 ng/ml RANKL were incubated for 20 minutes
with LysoTracker Red (Invitrogen) according to the manufac-
turer’s instructions, then fixed, stained with DAPI, and imaged
as described above.
Analysis of gene expression. To test gene expression
changes, mouse myeloid progenitors were cultured for 0–3
days in the presence of 50 ng/ml M-CSF with or without
50 ng/ml RANKL, followed by RNA extraction and reverse
transcription as previously described (26,28). Quantitative
reverse transcription–polymerase chain reaction was then per-
formed using TaqMan assays for the mouse genes Pik3ca
(Mm00435673_m1), Pik3cb (Mm00659576_m1), Pik3cg
(Mm00445038_m1), and Pik3cd (Mm00435674_m1) and the
osteoclast-specific genes Acp5, Ctsk, Itgb3, Calcr, Nfatc1,
and Tm7sf4 as previously described (26). Transcript levels
relative to GAPDH were calculated using the comparative Ct
method (26).
Cathepsin K secretion. Mouse myeloid progenitors
were cultured for 3 days in the presence of 50 ng/ml M-CSF
and 50 ng/ml RANKL and then stimulated with 50 ng/ml
phorbol myristate acetate (Sigma) for 10 minutes. The super-
natants were collected, and the proteins were precipitated
with acetone. Whole-cell lysates were obtained using Triton
X-100–based lysis buffer (29). Samples were subjected to
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and immunoblotted with mouse monoclonal antibodies against
cathepsin K (E-7; Santa Cruz Biotechnology) with secondary
reagents from GE Healthcare.
Micro–computed tomography (micro-CT) analysis.
Trabecular bone structure and mineralization were tested by
micro-CT analysis of the distal metaphysis of the femurs of
age- and sex-matched wild-type and PI3K/mice essentially
as described previously (26). Micro-CT sections were acquired
using a SkyScan 1172 micro-CT apparatus with an isometric
voxel size of 4.5 m, followed by reconstitution of a horizontal
section 250 sections proximal to the distal growth plate and
reconstitution of a 3-dimensional axial cylinder 700 m in
diameter expanding from 150 to 450 sections proximal to the
distal growth plate, as well as calculation of quantitative
micro-CT parameters using SkyScan NRecon and
CT-Analyser software (both from SkyScan) as described
previously (26).
Histomorphometric analysis. Histomorphometry
studies were performed on the distal metaphysis of the femurs
of age-matched wild-type and PI3K/ male mice at ages
8–10 weeks. Bones were fixed, decalcified in 14% EDTA,
embedded in paraffin, and sectioned and stained with
TRAP, toluidine blue, and hematoxylin and eosin. Histo-
morphometric analysis was performed using a Zeiss Axioskop
2 microscope equipped with a video camera and an
OsteoMeasure system (OsteoMetrics) according to interna-
tional standards as described previously (30).
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Statistical analysis. All experiments were performed
3 times (or on 3 individual mice), with comparable results.
Statistical analysis was performed using Student’s unpaired
2-sample t-test.
RESULTS
PI3K expression during osteoclast develop-
ment. We first tested the expression of the various PI3K
isoforms during in vitro differentiation of mouse progen-
itors in the presence of 50 ng/ml M-CSF with (osteo-
clasts) or without (macrophages) 50 ng/ml RANKL. As
shown in Figure 1A, the expression of PI3K but not of
the other PI3K isoforms was dramatically up-regulated
during osteoclast differentiation. In contrast, no substan-
tial changes were seen in parallel macrophage cultures
(Figure 1B). Therefore, consistent with a recent report
(31), PI3K was dramatically and specifically up-
regulated during osteoclast development.
Inhibition of PI3K blocks osteoclast develop-
ment and function in vitro. To assess the functional role
of PI3K in osteoclasts, we next tested the effect of the
PI3K inhibitor TGX221 on in vitro–generated osteo-
clasts. As shown in Figure 2A, the nonselective PI3K
inhibitor wortmannin completely blocked development
of osteoclasts (large multinucleated TRAP-positive
cells) generated by culturing mouse myeloid progenitors
in the presence of 50 ng/ml M-CSF and 50 ng/ml
RANKL. TGX221 also dose-dependently inhibited os-
teoclast development by 90% at a concentration of
50 nM, a dose thought to specifically inhibit PI3K
(8,32,33) (Figure 2) (further information is available at
semmelweis.hu/elettan/en/?p664).
We also tested the effect of TGX221 on the
resorptive activity of osteoclasts. As shown in Figure 2B,
50 nM wortmannin abrogated the resorption of an
artificial hydroxyapatite surface by murine osteoclast
cultures generated using 50 ng/ml M-CSF and 50 ng/ml
RANKL. TGX221 at 50 nM also nearly completely
blocked the resorptive activity of osteoclasts under such
conditions (Figure 2B).
We next tested the effect of TGX221 on human
osteoclasts differentiated from PBMCs in the presence
of 50 ng/ml human M-CSF and 50 ng/ml human
RANKL. Both wortmannin and TGX221 strongly re-
duced the number of osteoclasts, with 50 nM TGX221
causing 70% inhibition (Figure 2C) (further informa-
tion is available at semmelweis.hu/elettan/en/?p664).
In addition, 50 nM wortmannin or 50 nM TGX221
dramatically inhibited the in vitro resorptive capacity of
human osteoclasts on an artificial hydroxyapatite layer
(Figure 2D). Results similar to those described above
were obtained when the concentration of M-CSF and
RANKL was reduced to 20 ng/ml (further information is
available at semmelweis.hu/elettan/en/?p664). Taken
together, these findings show that PI3K likely plays an
important role in the in vitro development and resorp-
tive function of both human and mouse osteoclasts.
In vivo bone homeostasis in PI3K/ mice. To
test the role of PI3K in osteoclast biology and bone
homeostasis using a genetic approach, we turned to the
analysis of PI3K/ mice carrying a targeted deletion
within the catalytic domain of PI3K (22). We first
analyzed trabecular bone structure using micro-CT ana-
lysis of the distal metaphysis of the femurs at ages 8–10
weeks. As shown in Figure 3A, significantly more tra-
beculae were seen in PI3K/ mice, both in represen-
tative single micro-CT slices and in 3-dimensional recon-
stitution of an axial cylinder. Quantification of the entire
trabecular area (Figure 3B) revealed significantly in-
creased percent bone volume/total volume (BV/TV)
Figure 1. Expression of phosphoinositide 3-kinase  (PI3K) during in vitro osteoclast development. Gene expression was analyzed in wild-type
mouse myeloid precursors cultured for the indicated time periods in the presence of 50 ng/ml macrophage colony-stimulating factor with 50 ng/ml
RANKL (osteoclasts) (A) or without RANKL (macrophages) (B). The expression of the Pik3ca, Pik3cb, Pik3cg, and Pik3cd (encoding the catalytic
subunits of PI3K, PI3K, PI3K, and PI3K, respectively) was determined by quantitative reverse transcription–polymerase chain reaction. Bars
show the mean  SEM from 3 independent experiments.
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in PI3K/ mice in both females (P  0.000029;
n  8) and males (P  0.000084; n  8), which was
primarily due to increased trabecular number rather
than increased thickness of the individual trabeculae.
The increased BV:TV ratio was seen across all age
groups tested (further information is available at
semmelweis.hu/elettan/en/?p664).
We also performed histologic and histomorpho-
metric analysis of the trabecular bone of the distal
femurs. Trabecular density was increased in PI3K/
mice (Figure 3C); the quantitative BV:TV ratio (P 
0.0059; n 5) and trabecular number, but not trabecular
thickness, were also increased in PI3K/ mice
(Figure 3D).
We next analyzed osteoclasts visible in the
TRAP-stained histologic sections. There was a moderate
but not statistically significant (P  0.44; n  5) reduc-
tion in the average number of osteoclasts per bone
perimeter in PI3K/ mice (Figure 3D). Further ana-
lysis revealed that osteoclasts in PI3K/ mouse
Figure 2. Pharmacologic inhibition of phosphoinositide 3-kinase  (PI3K) blocks development and function of murine and human osteoclasts.
Shown are representative images and quantification of tartrate-resistant acid phosphatase (TRAP)–stained cell cultures of (A and C), and in vitro
resorption pit formation by (B and D) wild-type mouse bone marrow–derived osteoclasts (A and B) and human blood mononuclear cell–derived
osteoclasts (C and D) cultured for 3 days (A), 11 days (B), or 14 days (C and D) in the presence of 50 ng/ml macrophage colony-stimulating factor,
50 ng/ml RANKL, and the indicated concentrations of PI3K inhibitors or 0.1% vehicle. Resorption pits appear as lighter areas. Osteoclasts are
defined as TRAP-positive cells with 3 nuclei. In vitro resorption is defined as the percentage of resorbed area. Bars show the mean  SEM from
3 independent experiments. Images are representative of 8–20 (A), 4–9 (B), or 3–4 (C and D) independent experiments.
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sections were more rounded (Figure 3C, inset) with
significantly shorter bone contact length (P  0.030;
n  30 osteoclasts) (Figure 3D). In addition, the
depth of resorption pits was dramatically reduced in
PI3K/ mouse sections (P  0.0089; n  30 osteo-
clasts) (Figures 3C [inset] and D). Taken together, these
results indicate that PI3K/ mice have increased
trabecular bone volume, likely caused by moderately
reduced numbers and abnormal morphology/function of
osteoclasts.
PI3K deficiency impairs osteoclast develop-
ment and function in vitro. Next, we tested the effect of
the PI3K/ mutation on in vitro osteoclast develop-
ment and function. As shown in Figure 4A, PI3K
deficiency led to reduced numbers of osteoclasts gener-
ated in the presence of 50 ng/ml M-CSF and 50 ng/ml
RANKL (P  0.0015; n  5), and the average diameter
of those cells was even more dramatically reduced
(P  0.00083; n  5). Similar results were obtained
when the concentration of M-CSF and RANKL was
reduced to 20 ng/ml (further information is available at
semmelweis.hu/elettan/en/?p664). Fluorescence label-
ing of DNA (Figure 4A) also revealed significantly
decreased numbers of nuclei per osteoclast (P  0.018;
n  6).
We also tested osteoclast differentiation in
Figure 3. Phosphoinositide 3-kinase  (PI3K) is required for in vivo bone homeostasis in mice. A, Representative single micro–computed
tomography (micro-CT) cross-sections (left) and 3-dimensional reconstitution of an axial cylinder (right) of the trabecular area of the distal femoral
metaphysis of 9-week-old wild-type (WT) and PI3K/ female mice. B, Quantitative micro-CT analysis of the trabecular bone architecture of WT
and PI3K/ female and male mice ages 8–10 weeks. C, Representative images of histomorphometric analysis of the trabecular area of WT and
PI3K/ male mice at age 8 weeks. Original magnification  10. Insets show enlarged view of tartrate-resistant acid phosphatase–stained sections
with osteoclasts (arrows) and resorption pits (arrowheads). D, Histomorphometric analysis of the trabecular bone architecture and the number of
osteoclasts (OC), the length of attachment of osteoclasts to the trabecular bone surface (OC bone contact length), and the depth of the resorption
pits. Data were obtained from 8 (A and B) or 5 (C and D) mice per genotype. Bars show the mean  SEM.   P  0.05;   P  0.01;   P 
0.002;   P  0.0004. BV/TV  bone volume/total volume; NS  not significant.
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osteoblast–osteoclast cocultures. We observed a moder-
ate but not statistically significant (P  0.12; n  5)
reduction of the number of osteoclasts differentiated
from PI3K/ mouse bone marrow cells. However, the
diameter of osteoclasts was dramatically reduced in
PI3K/ mouse cell cultures (P  0.00012; n  5).
We next tested the resorptive activity of PI3K/
mouse cell cultures. PI3K deficiency strongly reduced
the resorptive capacity of in vitro osteoclast cultures in
the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL,
both on an artificial hydroxyapatite surface (P 
0.00042; n  5) (Figure 4C) and on bovine bone slices
(P  6.2  106; n  5) (Figure 4D). Results similar to
those described above were obtained when the concen-
tration of M-CSF and RANKL was reduced to 20 ng/ml
(further information is available at semmelweis.hu/
elettan/en/?p664). Taken together, these findings
demonstrate that genetic deficiency of PI3K impairs in
vitro development and resorptive function of osteoclasts.
PI3K is not required for osteoclast-specific
gene expression. To better understand the role of PI3K
in osteoclasts, we next tested the expression of
osteoclast-specific genes during differentiation of mu-
rine myeloid progenitors in the presence of 50 ng/ml
M-CSF and 50 ng/ml RANKL (osteoclasts) or M-CSF
alone (macrophages). As shown in Figure 5A, the ex-
pression of Acp5 (encoding TRAP), Ctsk (encoding
cathepsin K), Itgb3 (encoding integrin 3 chain), Nfatc1
(encoding NF-ATc1), Calcr (encoding calcitonin recep-
tor), and Tm7sf4 (encoding dendritic cell–specific trans-
Figure 4. Genetic deficiency of PI3K leads to defective osteoclast development and function. Shown are representative images and quantification
of tartrate-resistant acid phosphatase–stained cell cultures of (A and B) and in vitro resorption pit formation on artificial hydroxyapatite (C) or on
bovine bone slices (D) by, WT and PI3K/ mouse bone marrow–derived osteoclasts cultured for 3 days (A), 10 days (B), or 11 days (C and D)
in the presence of 50 ng/ml macrophage colony-stimulating factor and 50 ng/ml RANKL (A, C, and D) or with WT mouse calvarial osteoblasts (B).
Bars show the mean  SEM from 5–6 independent experiments. Images are representative of 8–10 (A), 3–4 (B), or 4–5 (C and D) independent
experiments.   P  0.05;   P  0.002;   P  0.0004. See Figure 3 for definitions.
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membrane protein) was strongly increased during osteo-
clast differentiation but not during macrophage
differentiation. PI3K deficiency did not affect the
expression of any of those genes (Figure 5A), indicating
that PI3K is not required for osteoclast-specific gene
expression.
Normal survival and apoptosis of PI3K/
mouse osteoclast-lineage cells. To test the role of PI3K
deficiency in survival and apoptosis of osteoclast-lineage
cells, preosteoclasts were generated by culturing myeloid
progenitors in 50 ng/ml M-CSF and 50 ng/ml RANKL
for 2 days, followed by withdrawal of serum and cyto-
kines for 12 or 18 hours. As shown in Figures 5B and C,
90% of the preosteoclasts before serum/cytokine with-
drawal (0-hour samples in Figure 5B) were negative for
the apoptosis marker annexin V and the necrosis marker
7-AAD, whereas serum/cytokine withdrawal triggered
apoptosis and then necrosis of the cells. No difference in
any of those processes was observed between cultures of
cells from wild-type and PI3K/mice (Figures 5B and
C).
We also tested apoptosis in regular osteoclast
cultures by in situ TUNEL staining. As shown in Figure
5D, 12% of cells were TUNEL positive in cultures of
osteoclasts from both wild-type and PI3K/ mice.
Taken together, the observations suggest that PI3K
deficiency does not affect survival, apoptosis, or necrosis
of osteoclast-lineage cells.
PI3K is required for actin ring formation. We
next tested whether PI3K is required for the formation
of the osteoclast actin ring, which is likely involved in
sealing the resorption pit. A continuous F-actin ring was
observed at the periphery of most wild-type mouse
osteoclasts in the presence of 50 ng/ml M-CSF and
Figure 5. PI3K is not required for up-regulation of osteoclast-specific gene expression and survival of osteoclasts. A, Gene expression in WT and
PI3K/ mouse bone marrow–derived cells cultured for the indicated time periods in the presence of 50 ng/ml macrophage colony-stimulating
factor (M-CSF) with 50 ng/ml RANKL (osteoclasts; OC) or without RANKL (macrophages; M). The expression of Acp5, Ctsk, Itgb3, Nfatc1, Calcr,
and Tm7sf4 (encoding tartrate-resistant acid phosphatase, cathepsin K, integrin 3 chain, NF-ATc1, calcitonin receptor, and dendritic cell–specific
transmembrane protein, respectively) was determined by quantitative reverse transcription–polymerase chain reaction. B and C, Representative flow
cytometric profiles (B) and quantification (C) of the binding of phycoerythrin (PE)–conjugated annexin V (apoptosis marker) and
7-aminoactinomycin D (7-AAD) (necrosis marker) to WT and PI3K/ mouse preosteoclasts (generated by culturing myeloid precursors in the
presence of 50 ng/ml M-CSF and 50 ng/ml RANKL for 2 days) before (0 hours) or after serum and cytokine starvation for 12 or 18 hours. Surviving
cells are defined as negative for both PE-conjugated annexin V and 7-AAD staining. D, Analysis of the number of TUNEL-positive cells in WT and
PI3K/mouse bone marrow–derived osteoclast cultures. Data are from 3 (A) or 5-6 (B–D) independent experiments. Bars show the mean SEM.
See Figure 3 for other definitions.
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50 ng/ml RANKL (Figures 6A and C). In contrast, even
multinucleated cells in PI3K/ mouse osteoclast cul-
tures rarely showed a clear F-actin ring, and F-actin was
instead accumulated in the cytoplasm and distinct
patches at the cell periphery (P  7.8  108; n  6).
We also assessed temporal changes of actin
polymerization using transgenic mice expressing
EGFP-tagged Lifeact, a short peptide specifically bind-
ing to fibrillar actin. As shown in Supplementary Videos
1 and 2 (available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38660/abstract) (further information is available at
Figure 6. PI3K is required for actin ring formation and cathepsin K secretion by murine osteoclasts. A and C (left), Representative fluorescence
images (A) and quantification (C [left]) of WT and PI3K/ mouse myeloid precursors cultured in the presence of 50 ng/ml macrophage
colony-stimulating factor and 50 ng/ml RANKL for 3 days and then stained with Alexa Fluor 488–conjugated phalloidin and DAPI. Arrows in A show
the actin ring. Values in C (left) are the percentage of osteoclasts with closed actin rings at the cell periphery. B and C (right), Representative
fluorescence images (B) and quantification (C [right]) of WT and PI3K/ mouse myeloid precursors cultured under conditions similar to those
described in A and then stained with LysoTracker Red and DAPI. An acidic vesicle is marked with an arrow in B. Values in C (right) are the number
of acidic vesicles. Boxed areas at left in A and B are shown at higher magnification at right. D, Immunoblot (left) and densitometric quantification
(right) of cathepsin K (Ctsk) in the supernatant or whole-cell lysates (WCL) of WT and PI3K/ mouse bone marrow cells cultured as described
in A. Fluorescence images are representative of 4–6 independent experiments; immunoblot is representative of 4 independent experiments. Bars
show the mean  SEM from 3–6 independent experiments.   P  0.01;   P  0.0004. See Figure 3 for other definitions.
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semmelweis.hu/elettan/en/?p664), osteoclasts derived
from Lifeact–EGFP–expressing wild-type mouse pro-
genitor cells began to form continuous F-actin rings 2
days after addition of RANKL, and these remained
visible until the osteoclasts succumbed to apoptosis. In
contrast, osteoclast-like cells from Lifeact–EGFP–
transgenic PI3K/ mice failed to form actin rings and
instead showed patchy/dispersed Lifeact distribution.
Taken together, these findings indicate that PI3K plays
an important role in the formation of the osteoclast actin
ring.
PI3K/ mouse osteoclasts retain acidic vesi-
cles and fail to release cathepsin K. During bone
resorption, osteoclasts deliver and exocytose lysosome-
related, cathepsin K–containing acidic vesicles to the
ruffled border (34). Since prior studies proposed a role
for PI3K activity in this process (31,35), we tested the
distribution of acidic vesicles in PI3K/ mouse cell
cultures in the presence of 50 ng/ml M-CSF and 50 ng/ml
RANKL. While wild-type mouse osteoclasts contained
very few small acidic vesicles, PI3K/ mouse cells
were fully packed with such vesicles, suggesting that they
cannot be discharged and therefore are retained in
PI3K/ mouse cells (P  0.0021; n  5) (Figures 6B
and C).
Exocytosisofthematrix-degradingenzymecathep-
sin K plays an important role in osteoclast-mediated
bone resorption. As shown in Figure 6D, the PI3K/
mutation substantially reduced the amount of cathepsin
K in the supernatant of osteoclast cultures (P  0.0064;
n  3). Taken together, these results show that the
absence of PI3K leads to defective actin ring forma-
tion, accumulation of acidic vesicles, and impaired re-
lease of cathepsin K into the extracellular space.
Inhibition of PI3K after osteoclast formation
blocks resorption and actin ring maintenance. The
above results suggested that PI3K not only is involved
in osteoclast development but also plays important
functional roles in mature osteoclasts. To test that
possibility, we investigated the effect of PI3K inhibition
after the formation of mature osteoclasts. As shown at
semmelweis.hu/elettan/en/?p664, adding 50 nM
TGX221 to osteoclast cultures starting from 3 days after
the initial RANKL treatment strongly inhibited resorp-
tion of an artificial hydroxyapatite layer (P 0.0093; n
3). As shown at semmelweis.hu/elettan/en/?p664,
treatment of osteoclasts with 50 nM TGX221 for 6 hours
starting 3 days after the initial RANKL treatment (when
mature osteoclasts with complete actin rings have al-
ready been formed) led to the disappearance of actin
rings (P  2.4  104; n  3). Kinetic analysis of the
effect of TGX221 using Lifeact–EGFP–expressing cells
revealed that the actin rings began to resolve immedi-
ately after TGX221 treatment and became highly frag-
mented within a few hours (further information is
available at semmelweis.hu/elettan/en/?p664) (see
Supplementary Videos 3 and 4, available on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.38660/abstract). Taken together,
these observations suggest that inhibition of PI3K
blocks the resorptive function and actin ring mainte-
nance of in vitro osteoclast cultures even if performed
several days after initial RANKL treatment.
DISCUSSION
Recent studies revealed highly specific functions
of the various PI3K isoforms, triggering development of
isoform-specific PI3K inhibitors for therapeutic pur-
poses (2,36). Although prior studies suggested a role for
PI3K activity in osteoclast development and bone re-
sorption (18–21), little is known about the specific PI3K
isoform(s) participating in those responses. Our initial
gene expression studies (Figure 1) suggested a func-
tional role for PI3K in osteoclasts, which was tested
using a detailed genetic and pharmacologic approach.
Those studies revealed a critical role for PI3K in in
vitro development and resorbing function of primary
human and mouse osteoclasts (Figures 2 and 4) and in in
vivo bone homeostasis in experimental mice (Figure 3).
Reduced osteoclast-mediated bone resorption
may be due to failure of osteoclast development or
defective resorptive function of mature osteoclasts.
While PI3K appears to play a role in osteoclast devel-
opment under certain conditions (Figures 2A and C,
Figures 4A and B), the most dramatic in vitro effects of
PI3K inactivation were observed when testing resorp-
tive function or cellular parameters related to bone
resorption (Figures 2, 4, and 6). Osteoclasts from
PI3K/ mice also showed reduced bone contact
length and resorption pit depth in vivo (Figure 3D).
Furthermore, addition of TGX221 to cultures with ma-
ture osteoclasts inhibited bone resorption and led to
rapid disassembly of preexisting actin rings (further
information is available at semmelweis.hu/elettan/en/
?p664). Those results suggest that the most critical
role for PI3K is to mediate the resorptive function of
mature osteoclasts.
We recently reported the analysis of phospho-
lipase C2–deficient (PLC2/) mouse osteoclast cul-
tures and bone morphology (26). It is interesting to note
that while PI3K/ and PLC2/ mice had similar
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increases in trabecular bone mass, PLC2/ mouse
cells showed a much more robust in vitro osteoclast
developmental defect than PI3K/mouse cells. Those
results again suggest that the primary defect in
PI3K/ mice lies in the bone-resorbing function of
osteoclasts.
The exact position of PI3K in osteoclast signal
transduction pathways is at present poorly understood.
Osteoclast development and function are triggered
through a large number of extracellular signals (9–
11,16,17). Our initial experiments suggested that PI3K
is required for phosphorylation of Akt in response to
M-CSF treatment (data not shown). However, a more
detailed analysis of signaling by the various cell surface
receptors and downstream signaling intermediates, as
well as high-resolution imaging of phosphatidylinositol
3,4,5-trisphosphate generation in osteoclast cultures,
would be needed to define the exact position of PI3K
in intracellular signaling of osteoclasts. Nevertheless,
our findings indicate that PI3K activation participates
in reorganization of the actin cytoskeleton and release of
cathepsin K–containing acidic vesicles (Figure 6) but not
in gene expression changes or survival/apoptosis of the
cells (Figure 5).
The results of prior studies using nonspecific
PI3K inhibitors suggested a role for PI3Ks in osteoclast
development and function (18–21). A few reported
attempts to narrow the list of PI3K isoform(s) involved
failed to reveal a major role for any of the specific PI3K
isoforms, showed contradictory results, and were even
inconsistent with a role for PI3K (31,37,38). Our
substantially more detailed experiments firmly identify
PI3K as a critical and likely predominant PI3K isoform
involved in osteoclast development and function.
There is substantial interest in the pharmaceuti-
cal industry in the development of isoform-specific PI3K
inhibitors for the treatment of various human diseases
(1,3–5). Based on its role in platelet activation (32,39–
43), PI3K has been proposed to be a suitable target for
the treatment of thrombotic diseases (44). Based on the
results presented here, PI3K may also be a suitable
therapeutic target in diseases characterized by excessive
osteoclast-mediated bone resorption such as rheumatoid
arthritis, osteoporosis, or cancer-induced focal bone
loss.
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